Y-mAbs Therapeutics announced that CFO, Bo Kruse, has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor. Mr. Kruse will remain in the CFO role until his successor is identified and joins the Company. He will then continue as a non-executive employee from the time his successor joins the Company through July 31, 2024, after which it is expected that Mr. Kruse will be available to the Company for a period of time to support a smooth transition of the CFO role.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on YMAB:
- Y-mAbs Therapeutics price target raised to $22 from $21 at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today
- Y-mAbs Therapeutics price target raised to $26 from $16 at BMO Capital
- Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
- Y-mAbs Therapeutics appoints Tagliaferri to board of directors
